Insulin icodec

依柯胰岛素

Report date: 2026/04/03 20:03:44

Base Information

Drug NameInsulin icodec
Drug Alias NameLong-acting basal insulin analogue-287 (Novo Nordisk)Long-acting basal insulin analogue (Novo Nordisk)Long-acting-insulin-287 (Novo Nordisk)AWIQLIAwiqli +[15] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonistsOrnithine decarboxylase stimulantsPhosphokinases stimulants +[4] 
TargetsInsulin receptorOrnithine decarboxylasePhosphokinases +[4] 
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Global Approved IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryCanada
Original Approved Date2024/03/12
Country/TerritoryCzechiaBelgiumBulgaria +[41] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesNovo Nordisk Canada IncNovo Nordisk IncNovo Nordisk A/S +[5] 
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeA10AE07
Related LinksWikipediaDrugBankKEGG